tm 9

TM-9 is a novel multi-function inhibitor for the treatment of Alzheimer's disease (AD). TM-9 exhibits potent and balanced inhibitory activities against ChE and MAO-B.

TM-N1324 is a GPR39 agonist. TM-N1324 activates human GPR39 with high efficacy and potencies of 280 nM and 9 nM in the absence and presence of Zn2+, respectively. TM-N1324 has similar potencies to murine GPR39 with EC50s of 180 nM and 5 nM, respectively.

CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective CRTH2 DP2 receptor antagonist. It binds to human CRTH2 DP2, DP1, and TP receptors with Ki values of 0.6, 1200, and >10,000 nM, respectively.

Lacto-N-fucopentaose II (LNFP II), a sialyl-Lewis hapten of the human Lewis blood group determinant, acts as a monosialo-ganglioside glycolipid and sialyl derivative, CA 19-9, and is recognized as a molecular tumor marker (TM) for biliopancreatic malignancy [1].

ICRF-196 is a Topoisomerase II Inhibitor and antineoplastic agent.